JPWO2020109978A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020109978A5 JPWO2020109978A5 JP2021529265A JP2021529265A JPWO2020109978A5 JP WO2020109978 A5 JPWO2020109978 A5 JP WO2020109978A5 JP 2021529265 A JP2021529265 A JP 2021529265A JP 2021529265 A JP2021529265 A JP 2021529265A JP WO2020109978 A5 JPWO2020109978 A5 JP WO2020109978A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion polypeptide
- seq
- sequence
- tag
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 70
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 70
- 230000004927 fusion Effects 0.000 claims description 48
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 102100026256 Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 Human genes 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 101710161659 Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 208000016667 Familial chylomicronemia syndrome Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010048214 Xanthoma Diseases 0.000 claims description 3
- 206010048215 Xanthomatosis Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 206010019847 hepatosplenomegaly Diseases 0.000 claims description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000003234 polygenic effect Effects 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 208000024866 recurrent acute pancreatitis Diseases 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 101001003882 Homo sapiens Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 Proteins 0.000 claims 4
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 8
- 230000035772 mutation Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771359P | 2018-11-26 | 2018-11-26 | |
| US62/771,359 | 2018-11-26 | ||
| PCT/IB2019/060140 WO2020109978A1 (en) | 2018-11-26 | 2019-11-25 | Lpl-gpihbp1 fusion polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513626A JP2022513626A (ja) | 2022-02-09 |
| JPWO2020109978A5 true JPWO2020109978A5 (enExample) | 2022-12-05 |
Family
ID=68807212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529265A Pending JP2022513626A (ja) | 2018-11-26 | 2019-11-25 | Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220025344A1 (enExample) |
| EP (1) | EP3887393A1 (enExample) |
| JP (1) | JP2022513626A (enExample) |
| CN (1) | CN113396158A (enExample) |
| WO (1) | WO2020109978A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117384912A (zh) * | 2023-12-13 | 2024-01-12 | 中国人民解放军东部战区总医院 | Gpihbp1突变型基因及其应用 |
| WO2025124559A1 (zh) * | 2023-12-13 | 2025-06-19 | 维亚臻生物技术（苏州）有限公司 | 捕获探针、含有其的家族性乳糜微粒血症综合征检测试剂盒及应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| HRP20110368T1 (hr) | 2007-06-21 | 2011-06-30 | Technische Universitt Mnchen | Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AU2011254564B2 (en) | 2010-05-21 | 2014-03-27 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| JO3412B1 (ar) * | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| AU2015274574B2 (en) | 2014-06-10 | 2019-10-10 | Amgen Inc. | Apelin polypeptides |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2018020477A1 (en) * | 2016-07-28 | 2018-02-01 | The Regents Of The University Of California | Methods and compositions for treating hypertriglyceridemia |
-
2019
- 2019-11-25 WO PCT/IB2019/060140 patent/WO2020109978A1/en not_active Ceased
- 2019-11-25 EP EP19816456.8A patent/EP3887393A1/en not_active Withdrawn
- 2019-11-25 US US17/296,369 patent/US20220025344A1/en not_active Abandoned
- 2019-11-25 CN CN201980089752.0A patent/CN113396158A/zh active Pending
- 2019-11-25 JP JP2021529265A patent/JP2022513626A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5564268B2 (ja) | 成長因子と結合する融合タンパク質 | |
| CN102917726B (zh) | 干扰素类似物 | |
| CN113646008A (zh) | pHLIP®肽介导的细胞表面的表位束缚 | |
| JP2014500868A (ja) | 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド | |
| TW201617364A (zh) | 用於治療代謝異常之組成物及方法 | |
| WO1999048923A1 (en) | Multivalent ligands which modulate angiogenesis | |
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| US8003610B2 (en) | Bradykinin B2 receptor antagonist peptide from amphibian skin | |
| CN102584976B (zh) | 一种人血清淀粉样蛋白a1及其制备方法和应用 | |
| JP2025156282A (ja) | 免疫調節用組成物および方法 | |
| CN100413888C (zh) | 可溶性多肽 | |
| CN109232744B (zh) | 改进型齐考诺肽 | |
| CN115427428A (zh) | 新的细胞穿透肽及其用途 | |
| JPWO2020109978A5 (enExample) | ||
| JPWO2011013728A1 (ja) | 経粘膜吸収性を付与したモチリン類似ペプチド化合物 | |
| CN111378049A (zh) | 抗肿瘤靶向融合蛋白、其偶联物及用途 | |
| US5587457A (en) | Neutrophil stimulating peptides | |
| JP7637435B2 (ja) | 長時間作用型アドレノメデュリン誘導体の製造方法 | |
| JP2008502323A5 (enExample) | ||
| JP2005501544A (ja) | Ｐ−セレクチンに対して選択的に結合するペプチド化合物 | |
| CN120390752A (zh) | 靶向具有半胱天冬酶激活和募集结构域(asc)的凋亡相关斑点样蛋白的组合物及使用方法 | |
| JP5385611B2 (ja) | Ｐｆ４とｒａｎｔｅｓとの相互作用に対するアンタゴニスト | |
| JPH06502385A (ja) | 血管拡張及び免疫抑制ペプチド | |
| CA2564179C (en) | Biologically active peptide vapeehptllteaplnpk derivatives | |
| WO2004069857A2 (en) | “peptides, compositions and uses thereof” |